CREO - Ticker AI Digest

Creo Medical Group PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (CREO) 1
CREO 06:01
Creo Medical Group PLC
Change of Nominated Adviser
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 1
CREO 06:01
Creo Medical Group PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Ordinary Shares
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 1
CREO 06:01
Creo Medical Group PLC
U.S. FDA clearance for SpydrBladeâ„¢ Flex
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Creo Medical Group plc, a medical device company, announces that its SpydrBladeâ„¢ Flex device has received clearance from the U.S. Food & Drug Administration (FDA). SpydrBladeâ„¢ Flex is a versatile endoscopic tool designed for precision and adaptability in therapeutic endoscopy procedures, offering laparoscopic cut and seal functionality. The FDA clearance allows Creo to initiate the products launch in the U.S. market, leveraging its direct sales force and network of key opinion leaders. The device addresses a range of use-cases, many of which fall under established reimbursement codes, encouraging the adoption of next-generation products.
Creo Medical Groups CEO, Craig Gulliford, highlights the significance of this milestone, stating that SpydrBladeâ„¢ Flex, along with their suite of advanced energy GI products, significantly differentiates the company in the market. He also emphasizes the products design challenges and the associated IP, as well as the potential for widespread adoption in the USA.
The company, Creo Medical, is focused on improving patient outcomes through the development and commercialization of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. Their CROMA technology, powered by Kamaptive, optimizes surgical capability and patient outcomes by providing clinicians with increased flexibility, precision, and control.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 5
CREO 06:01
Creo Medical Group PLC
Change of Nominated Adviser
CREO 10:09
Creo Medical Group PLC
Result of AGM
CREO 06:01
Creo Medical Group PLC
AGM Statement and Directorate Changes
CREO 06:01
Creo Medical Group PLC
U.S. FDA clearance for SpydrBladeâ„¢ Flex
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Creo Medical Group plc, a medical device company, announces that its SpydrBladeâ„¢ Flex device has received clearance from the U.S. Food & Drug Administration (FDA). SpydrBladeâ„¢ Flex is a versatile endoscopic tool designed for precision and adaptability in therapeutic endoscopy procedures, offering laparoscopic cut and seal functionality. The FDA clearance allows Creo to initiate the products launch in the U.S. market, leveraging its direct sales force and network of key opinion leaders. The device addresses a range of use-cases, many of which fall under established reimbursement codes, encouraging the adoption of next-generation products.
Creo Medical Groups CEO, Craig Gulliford, highlights the significance of this milestone, stating that SpydrBladeâ„¢ Flex, along with their suite of advanced energy GI products, significantly differentiates the company in the market. He also emphasizes the products design challenges and the associated IP, as well as the potential for widespread adoption in the USA.
The company, Creo Medical, is focused on improving patient outcomes through the development and commercialization of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. Their CROMA technology, powered by Kamaptive, optimizes surgical capability and patient outcomes by providing clinicians with increased flexibility, precision, and control.
CREO 06:01
Creo Medical Group PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of Ordinary Shares

AI Crunch

Single-Ticker AI Crunch
CREO signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Creo Medical Group PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full CREO AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for CREO on 2025-06-30.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
60839812
Enterprise Value
63116001
Public Float
90.55
Broker Target
50
Shares Out
412473319
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BZ1BLL44
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2025-10-06
Net Debt
-4300000.0
Cash
8700000.0
EPS
-
Net Income
-28700000.0
Revenue
4000000.0
Enterprise Value
63116001
Trailing PE
-
Forward PE
-
Price Sales TTM
13.226
Price Book MRQ
1.0244
EV Revenue
10.0188
EV EBITDA
13.1676

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
11.5108
Institutions As Of
2025-05-27
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
3
Sale Director Dealing
1
Purchase TR1
1
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit CREO.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-06-30 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Creo Medical Group PLC has fresh news flow feeding the chart narrative.
06:01 Today's Catalyst Change of Nominated Adviser
AI Charts Studio
CREO Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-06-30 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -2.34%
RSI Gauge
Price Change
AI Forecast